Literature DB >> 31489317

Sorafenib and metformin: to be, or not to be, that is the question.

Giulia Orsi1, Andrea Casadei-Gardini1.   

Abstract

Entities:  

Year:  2019        PMID： 31489317      PMCID： PMC6700026          DOI： 10.21037/hbsn.2019.04.01

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

Review 1.  Metformin pathways: pharmacokinetics and pharmacodynamics.

Authors:  Li Gong; Srijib Goswami; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

2.  Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.

Authors:  Hsiao-Ping Chen; Jeng-Jer Shieh; Chia-Che Chang; Tzu-Ting Chen; Jaw-Town Lin; Ming-Shiang Wu; Jeng-Horng Lin; Chun-Ying Wu
Journal:  Gut       Date:  2012-07-07       Impact factor: 23.059

3.  Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.

Authors:  Andrea Casadei Gardini; Giorgia Marisi; Emanuela Scarpi; Mario Scartozzi; Luca Faloppi; Nicola Silvestris; Gianluca Masi; Caterina Vivaldi; Oronzo Brunetti; Stefano Tamberi; Francesco Giuseppe Foschi; Emiliano Tamburini; Elena Tenti; Salvatore Ricca Rosellini; Paola Ulivi; Stefano Cascinu; Oriana Nanni; Giovanni Luca Frassineti
Journal:  Expert Opin Pharmacother       Date:  2015-10-29       Impact factor: 3.889

Review 4.  Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.

Authors:  Serena De Matteis; Anna Maria Granato; Roberta Napolitano; Chiara Molinari; Martina Valgiusti; Daniele Santini; Francesco Giuseppe Foschi; Giorgio Ercolani; Umberto Vespasiani Gentilucci; Luca Faloppi; Mario Scartozzi; Giovanni Luca Frassineti; Andrea Casadei Gardini
Journal:  Dig Dis Sci       Date:  2017-05-19       Impact factor: 3.199

5.  Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation.

Authors:  Tsung-Ming Chen; Chun-Che Lin; Pi-Teh Huang; Chen-Fan Wen
Journal:  J Gastroenterol Hepatol       Date:  2011-05       Impact factor: 4.029

6.  Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis.

Authors:  Won Il Jang; Mi-Sook Kim; Jung Sub Lim; Hyung Jun Yoo; Young Seok Seo; Chul Ju Han; Su Cheol Park; Chul Seung Kay; Myungsoo Kim; Hong Seok Jang; Dong Soo Lee; Ah Ram Chang; Hae Jin Park
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

7.  Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.

Authors:  Sunbin Ling; Lei Song; Ning Fan; Tingting Feng; Lu Liu; Xu Yang; Mingjie Wang; Yanling Li; Yu Tian; Feng Zhao; Ying Liu; Qihong Huang; Zhaoyuan Hou; Fei Xu; Lei Shi; Yan Li
Journal:  Int J Oncol       Date:  2016-12-09       Impact factor: 5.650

Review 8.  Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.

Authors:  Yao-Yao Zhou; Gui-Qi Zhu; Tian Liu; Ji-Na Zheng; Zhang Cheng; Tian-Tian Zou; Martin Braddock; Shen-Wen Fu; Ming-Hua Zheng
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

9.  Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

Authors:  Floris H Groenendijk; Wouter W Mellema; Eline van der Burg; Eva Schut; Michael Hauptmann; Hugo M Horlings; Stefan M Willems; Michel M van den Heuvel; Jos Jonkers; Egbert F Smit; René Bernards
Journal:  Int J Cancer       Date:  2014-08-08       Impact factor: 7.396

10.  Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.

Authors:  Young-Seok Seo; Yun-Jung Kim; Mi-Sook Kim; Kyung-Suk Suh; Sang Bum Kim; Chul Ju Han; Youn Joo Kim; Won Il Jang; Shin Hee Kang; Ha Jin Tchoe; Chan Mi Park; Ae Jung Jo; Hyo Jeong Kim; Jin A Choi; Hyung Jin Choi; Michael N Polak; Min Jung Ko
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889
View more
  3 in total

1.  Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis.

Authors:  Ryan Lamm; Peter J Altshuler; Keyur Patel; Osama Shaheen; Angel Paulo Amante; Jesse Civan; Warren Maley; Adam Frank; Carlo Ramirez; Jaime Glorioso; Ashesh Shah; Hien Dang; Adam S Bodzin
Journal:  Transpl Int       Date:  2022-07-05       Impact factor: 3.842

Review 2.  Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.

Authors:  Daniel Geh; Derek M Manas; Helen L Reeves
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 8.265

3.  Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats.

Authors:  Agnieszka Karbownik; Danuta Szkutnik-Fiedler; Andrzej Czyrski; Natalia Kostewicz; Paulina Kaczmarska; Małgorzata Bekier; Joanna Stanisławiak-Rudowicz; Marta Karaźniewicz-Łada; Anna Wolc; Franciszek Główka; Edmund Grześkowiak; Edyta Szałek
Journal:  Pharmaceutics       Date:  2020-06-28       Impact factor: 6.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.